Propel Contour Sinus Implant
Intersect Ent. · Decision date Nov 7, 2025
What did the FDA approve?
FDA records P100044/S058 as a supplement to PMA P100044, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 7, 2025.
FDA approval order statement
to designate pre-deployment dimensional specifications as reference values for the Propel Contour Sinus Implant
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Nov 7, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P100044/S058
- Regulatory pathway
- PMA supplement
- Applicant
- Intersect Ent.
- Product code
- OWO
- Decision code
- APPR
- Decision date
- Nov 7, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-eluting sinus stent.
- Applicant
- Intersect Ent.
- Product code
- OWO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100044. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100044 · Original PMA
PROPEL
P100044/S058 received
Application receipt date recorded by FDA.
P100044/S058 · FDA decision
Real-Time Process
P100044/S059 · Related supplement
Propel, Propel Mini (including Propel Mini with Straight Delivery System), and Propel Contour Sinus Implants
P100044/S060 · Related supplement
Propel Family Products
Timeline entries are records held by MedtechLedger for P100044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROPELP100044 | Intersect Ent. | PMA approval | Aug 11, 2011 | FDA |
| Intersect Ent. | PMA supplement | Jul 31, 2026 | FDA | |
PROPELP100044/S061 | Intersect Ent. | PMA supplement | Sep 22, 2026 | FDA |
Propel Family ProductsP100044/S060 | Intersect Ent. | PMA supplement | Sep 23, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Intersect Ent.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1555 Adams Dr., Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P100044/S058
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

